It has come to a point that analyst do not want to hear about leading edge NOT leading to leading edge returns. These presentations have to be geared to how we make money and shareholder return FIRST. Otherwise we are talking research ,very important but is it financed by investors looking for ROI or charity.
I guess next week they will get a reward from IBD for a return on investors capital. This is all great if the shareholders get anything for the risk they take. If not it is all just feel good !!!!!
For sure the wonderful advancements made by their research and development team or how these developments are so important that the industry has to spend the money now today or be left behind. Finally we will hear about real sales and how that will turn into profit. Performance and shareholder returns ,is why they are going to these conferences.
best product, huge potential , but no notice of a sale. The company is like a university research project good ideas leading edge a place for engineers to think and invent. But for sure it is a failure as a business school !!!!
all kinds of confirmations / how any investor does not take advantage is beyond me. Pristine financials , lots of positive talk from the company and the industry. Some folks must see some better investment out there , but I have no idea what that is based on.
I like what you say ,but if you feel their is a positive future , why have not any of the established medical device companies not invested in the stock in a big way or bought the company??????? I see no indication of any interest from anyone in the industry.
so are you saying they now get both every 3 month options not based on performance and also additional stock based on performance ?????? please explain
The industry knows much more about potential and future than anyone on this message board ,they are not stepping in . Why not ,either they see no potential demand or think the technology has no barriers to entry. They are all looking all over the world for opportunity and not finding it with GTHP
Looking for worldwide sales but cannot get to first base in the USA. Not only are they getting no place with FDA but this company is known by every major medical testing device manufacturer in the world. It is obvious that they think this product has no real potential value , evidence is obvious, they have not bought the company. If they thought there is potential they would not wait for FDA but would develop other sales and eventually get FDA approval. Seems these majors really think the market is not really that big or this has no barriers to entry.
A buy sign for sure , my last sale was over $ 87.00 buy now and you will also be able to sell for more then that. Huge long term demand , pristine financials, huge barriers to entry. Just do your homework and have patience.
Sentiment: Strong Buy
The spread will increase between cost and sales. I expect in their position as leader in reclamation they will have the best access to inventory. But I think all the industry will do very well. I am told the substitutes are not efficient and do not perform close to R22. So it will come down to new equipment or high priced R22. The huge amount of equipment with plenty of life left will maintain the demand for years. Just be patient
Sentiment: Strong Buy
I agree, just wonder why the highly paid wall street gurus have not jumped on this. This is not rocket science just plain old supply and demand (high school economics) maybe the fact it is simple is the problem. All you have to do is research the HUGE amount of R22 equipment and research the known yearly use of R22. Please help me understand. They invest huge amount of money in biotech very risky and hard to understand !!!
Sentiment: Strong Buy
Bunge is the definition of high volume production. Do you really think they just sit around and let SZYM run the show ???
I would at least like to hear that these oils are actually being tested by major QSR . Every food producer or retail restaurant is looking for leading edge products that are healthy and not much more expensive. Bunge sales people have access to every major user . It is very hard for big users to change rcipies. It is one thing for these new products to be terrific in the test phase. But going on line is much different and needs plenty of time. But food service operators in hospitals and colleges are usually willing to do the testing and then actually put products they are impressed with right out on the line. With a new fall college season starting in the next 2 weeks I see no reason why one of the universities in California have not agreed to use the flour and oil.